Overcoming Resistance in Chronic Lymphocytic Leukemia - Maybe Less is More?

Acquired mutations in BTK, PLCG2 and BCL2 are associated with resistance to continuous targeted agent therapy in chronic lymphocytic leukemia (CLL). Here, we discuss new evidence that limiting the duration of CLL therapy may prevent the evolution of such resistance mutations, potentially facilitating effective re-treatment strategies.